Royalty Pharma plc
RPRX
Rank in Stocks
#867
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a... Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Share Price
$62.21
Last synced: 2026-10-20
Market Cap
$27.70B
Change (1 day)
3.22%
Change (1 year)
65.98%
Country
US
Trade Royalty Pharma plc (RPRX)
Category
Healthcare
Revenue for Royalty Pharma plc (RPRX)
Revenue in Jun 2026 TTM: $2.54B
According to Royalty Pharma plc latest financial reports the company's current revenue (TTM) is $2.54B. In 2024 the company made a revenue of $2.26B a decrease compared to the revenue in the year 2023 that was $2.35B. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Royalty Pharma plc from 2015 to 2026
Revenue at the end of each year
| Year | Revenue | Change |
|---|---|---|
| 2026 (TTM) | $2.54B | 6.64% |
| 2025 | $2.38B | 5.06% |
| 2024 | $2.26B | -3.86% |
| 2023 | $2.35B | 5.24% |
| 2022 | $2.24B | -2.28% |
| 2021 | $2.29B | 7.87% |
| 2020 | $2.12B | 16.98% |
| 2019 | $1.81B | 1.08% |
| 2018 | $1.79B | 12.33% |
| 2017 | $1.60B | -14.89% |
| 2016 | $1.88B | 13.62% |
| 2015 | $1.65B | 0.00% |
Revenue for similar companies or competitors
| Company | Revenue | Revenue Difference | Country |
|---|---|---|---|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| $830.81M | -67.24% |
US
|
|
| $4.88B | 92.59% |
HK
|
